Abstract
Calcium carbonate and aluminum hydroxide do not affect the pharmacokinetics of levetiracetam [1].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.
Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46:93–9.
Mink S, Muroi C, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurismal subarachnoid haemorrhage. Clin Neurol Neurosurg. 2011;113:644–8.
Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77–85.
Sabers A, Christensen J. No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res. 2011;95:277–9.
Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55–63.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Patsalos, P.N. (2013). Levetiracetam. In: Antiepileptic Drug Interactions. Springer, London. https://doi.org/10.1007/978-1-4471-2434-4_38
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2434-4_38
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2433-7
Online ISBN: 978-1-4471-2434-4
eBook Packages: MedicineMedicine (R0)